Status:
UNKNOWN
Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5)
Lead Sponsor:
University Hospital, Clermont-Ferrand
Collaborating Sponsors:
Amgen
Conditions:
Solid Malignancies
Eligibility:
All Genders
Up to 18 years
Phase:
PHASE2
Brief Summary
Hypothesis : pegfilgrastim at 200 µg/kg between 12 and 18 days after previous chemotherapy provides an efficient stem cell mobilization in children with malignancies Design: phase 2 study. Judgment cr...
Detailed Description
Patients: consecutively referred for HSC mobilization. 12 to 18 days after the previous chemotherapy. No haematological growth factor during the 8 previous days. Mobilization: one sc injection of 200...
Eligibility Criteria
Inclusion
- 0 to 18 years
- solid malignancy
- Lansky score \>70%
- 12 to 18 days since the beginning of the last chemotherapy cycle
- no administration of any hematopoietic growth factor in the previous 8 days
Exclusion
- clinical or biological conditions precluding the mobilization or collection procedure
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00751894
Last Update
January 19 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU
Clermont-Ferrand, France, 63058